ere driven by upside Tecfidera ($144M vs cons), Tysabri ($91M cons, incl. a lx $54M or $0.15 catch-up from a reimbursement dispute with Italy) and Avonex (+$30M vs cons). Spending was slightly ahead driven by SG&A (+$83M vs cons), offset by a lower tax rate (27% vs 29% in 1O14). Mgt. increased its 2

an diseases • Multiple Sclerosis (MS) • US prevalence of approx. 400,000 patients; Potential market of approx. $1.5.3 billion based on Copaxone, Avonex, & Rebif comparables • ldlopathk Pulmonary Fibrosis (IPF) • US incidence of approx. 20,000-50,CCOcases annually; Global market was valued at $2 b